Search
Search results
136 results found
Shiva and Sudha Swamynathan attend ISER 2024 meeting
Shiva and Sudha Swamynathan attended the 2024 ISER biennial meeting in Buenos Aires, Argentina where they presented their recent findings and interacted with colleagues from around the world. Shiva also chaired a session on corneal epithelial wound healing. It was a busy week of attending talks...
Farewell, Satinder!
After two years of post-doctoral training in our lab, Satinder Kaur is heading west to Stanford University, to continue her training and be closer to her husband! In the two years that she spent with us, Satinder produced high quality work that resulted in a first author review, one co-authored...
Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double-blind trials. Mov Disord 2011;26:1464-76.
Sampaio, C, J Bronzova, RA Hauser, AE Lang, O Rascol, SV Van De Witte, and AA Theeuwes. 2011. “Pardoprunox in Early Parkinson’s Disease: Results from 2 Large, Randomized Double-Blind Trials. Mov Disord 2011;26:1464-76.”. Mov Disord.
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes
Rascol, O, CJ Fitzer-Attas, RA Hauser, J Jankovic, A Lang, JW Langston, E Melamed, et al. 2011. “A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson’s Disease (the ADAGIO Study): Prespecified and Post-Hoc Analyses of the Need for Additional Therapies, Changes in UPDRS Scores, and Non-Motor Outcomes”. Lancet Neurol.
Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours.
Friedman, JH, P Agarwal, R Alcalay, KJ Black, KL Chou, L Cote, P Dayalu, et al. 2011. “Clinical Vignettes in Parkinson’s Disease: A Collection of Unusual Medication-Induced Hallucinations, Delusions, and Compulsive Behaviours.”. Int J Neurosci.
Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
Hauser, RA, AL Ellenbogen, LV Metman, A Hsu, MJ O’Connell, NB Modi, HM Yao, SH Kell, and SK Gupta. 2011. “Crossover Comparison of IPX066 and a Standard Levodopa Formulation in Advanced Parkinson’s Disease.”. Mov Disord.
Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay.
Brin, MF, CL Comella, J Jankovic, F Lai, M Naumann, and BoNTA Study Group. 2008. “Long-Term Treatment With Botulinum Toxin Type A in Cervical Dystonia Has Low Immunogenicity by Mouse Protection Assay.”. Mov Disord.
Transplanted dopaminergic neurons develop PD pathologic changes: a second case report
Kordower, JH, Y Chu, RA Hauser, CW Olanow, and TB Freeman. 2008. “Transplanted Dopaminergic Neurons Develop PD Pathologic Changes: A Second Case Report”. Mov Disord.
Pregabalin (Lyrica) in the treatment of Essential Tremor.
Zesiewicz, TA, CL Ward, RA Hauser, JA Pease Campbell, and KL Sullivan. 2007. “Pregabalin (Lyrica) in the Treatment of Essential Tremor.”. Movement Disorders.